Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Aligos Therapeutics, Inc.

Market Cap 32.67M 28.19M 25.96M 24.36M 45.71M 3.09B 46.21M 307M 120M 1.51B 123M 120M 5.24B P/E Ratio 2026 *
-0.73x
P/E Ratio 2027 * -1.2x
Enterprise Value 9.39M 8.1M 7.46M 7M 13.14M 889M 13.28M 88.23M 34.41M 434M 35.24M 34.49M 1.51B EV / Sales 2026 *
0.43x
EV / Sales 2027 * -49.9x
Free-Float
78.05%
Yield 2026 *
-
Yield 2027 * -
05-28 Lake Street Initiates Aligos Therapeutics With Buy Rating, $45 Price Target MT
05-27 Aligos Therapeutics, Inc. Presents Positive Data On Pevifoscorvir Sodium And Pipeline Programs At EASL Congress 2026 CI
05-07 Aligos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-17 Xiamen Amoytop Biotech Signs License Deal for Hepatitis B Drug MT
04-16 Aligos Therapeutics, Inc. and Xiamen Amoytop Biotech Co., Ltd. Enter Exclusive License Agreement for Pevifoscorvir Sodium in Greater China CI
04-14 Aligos Therapeutics announces first interim analysis results from the phase 2 B-Supreme study of pevifoscorvir sodium in participants with chronic hepatitis B virus infection and grant of FDA fast track designation RE
04-14 Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation CI
03-05 Aligos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
03-04 Aligos Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
02-04 Aligos Therapeutics, Inc. Announces Management Changes CI
01-21 Aligos Therapeutics provides phase 2 B-SUPREME study progress updates RE
01-21 Aligos Therapeutics, Inc. Announces Resignation of Hardean Achneck as Executive Vice President, Chief Medical Officer CI
01-21 Aligos Therapeutics, Inc. Provides Phase 2 B-Superme Study Progress Updates CI
1 day-3.22%
1 week+4.07%
Current month-10.35%
1 month-23.62%
3 months-32.50%
6 months-61.56%
Current year-45.17%
1 week 4.91
Extreme 4.91
5.55
1 month 4.8
Extreme 4.8
6.11
Current year 4.8
Extreme 4.8
10.49
1 year 4.8
Extreme 4.8
13.69
3 years 3.76
Extreme 3.76
46.8
5 years 3.76
Extreme 3.76
722.5
10 years 3.76
Extreme 3.76
937.75
Manager TitleAgeSince
Chief Executive Officer 64 2018-02-04
Director of Finance/CFO 60 2020-05-31
Chief Tech/Sci/R&D Officer 65 2018-04-30
Director TitleAgeSince
Director/Board Member 64 2018-07-31
Director/Board Member 74 2018-07-31
Chairman 64 -
Date Insider Type Main position Quantity % Market Cap.
03-08Free

Chief Financial Officer

37,485 0.7002%
03-08Free

Chief Technology Officer

23,310 0.4354%
03-08Free

Controller/Auditor

9,450 0.1765%
Change 5-day change 1-year change 3-year change Capi.($)
-3.22%+4.07%-33.72%-81.42% 32.67M
+0.96%+1.94%-12.97%-13.01% 43.03B
+4.02%+7.26%+294.33%+533.90% 32.71B
-1.69%-2.76%+13.70%-16.14% 30.29B
+1.41%-0.70%-0.53%+28.87% 29.4B
+1.16%+2.10%+14.27%+22.05% 25.08B
+2.40%+6.10% - - 13.54B
+0.03%+2.92%+56.75%+114.15% 13.35B
-1.09%-2.37%+5.07%+5.25% 12.97B
+0.93%-0.70%+107.81%+81.19% 12.11B
Average +0.02%+1.50%+49.41%+74.98% 21.25B
Weighted average by Cap. +0.32%+0.82%+60.09%+102.48%

Financials

2026 *2027 *
Net sales 21.68M 18.7M 17.23M 16.16M 30.33M 2.05B 30.66M 204M 79.43M 1B 81.34M 79.61M 3.47B 5M 4.31M 3.97M 3.73M 7M 474M 7.07M 46.98M 18.32M 231M 18.76M 18.36M 802M
Net income -93.95M -81.07M -74.66M -70.06M -131M -8.9B -133M -883M -344M -4.35B -353M -345M -15.06B -124M -107M -98.7M -92.62M -174M -11.76B -176M -1.17B -455M -5.75B -466M -456M -19.91B
Net Debt -23.28M -20.09M -18.5M -17.36M -32.57M -2.2B -32.93M -219M -85.32M -1.08B -87.37M -85.51M -3.73B -282M -243M -224M -210M -395M -26.72B -399M -2.65B -1.03B -13.05B -1.06B -1.04B -45.23B
Logo Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Employees
82
Date Price Change Volume
26-06-15 5.130 $ -2.84% 86,807
26-06-12 5.280 $ 0.00% 76,681
26-06-11 5.280 $ +2.33% 50,030
26-06-10 5.160 $ +0.39% 32,523
26-06-09 5.140 $ +3.63% 81,240
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.280USD
Average target price
56.29USD
Spread / Average Target
+966.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALGS Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!